Summit Therapeutics SMMT
$9.95 −$0.62 (-5.87%)
Market closed · Nov 21, 9:10 am ET · Last extended-hours $10.08 +1.31%
Open$10.28
Prev close$10.57
Day range$9.89 – $10.61
Volume7.22M
Market cap$7.96B
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$0.00
Operating profit-$214.61M+8.4% YoY
Net profit-$208.39M+10.1% YoY
Diluted EPS-$0.26+16.1% YoY
Free cash flow-$160.21M-72.0% YoY
Operating cash flow-$159.81M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Return on equity-220.0%
Return on assets-174.5%
Return on invested capital-212.9%
Current ratio5.99
Liabilities / assets18.5%
Cash & investments$629.79M
Total debt$16.13M
Net cash (debt)$613.65M
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Operating Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Expense | $214.61M | $220.50M | $195.21M | $1.09B | $224.88M |
| Selling and Admin Expenses | $45.48M | $62.76M | $62.59M | $556.70M | $77.58M |
| -General & Admin Expense | $45.48M | $62.76M | $62.59M | $556.70M | $77.58M |
| Research & Development | $169.13M | $157.73M | $132.62M | $537.67M | $147.29M |
| Operating Profit | -$214.61M | -$220.50M | -$195.21M | -$1.09B | -$224.88M |
| Other Income (Expense) | $6.23M | $4.80M | $5.79M | $14.84M | $5.75M |
| Gain on Sale of Security | $6.23M | $4.30M | $5.79M | $14.89M | $5.75M |
| Pretax Profit | -$208.39M | -$215.70M | -$189.42M | -$1.08B | -$219.12M |
| Net Profit | -$208.39M | -$215.70M | -$189.42M | -$1.08B | -$219.12M |
| Profit from Continuing Operations | -$208.39M | -$215.70M | -$189.42M | -$1.08B | -$219.12M |
| Net Income to Parent Company | -$208.39M | -$215.70M | -$189.42M | -$1.08B | -$219.17M |
| Net Income to Common Stockholders | -$208.39M | -$215.70M | -$189.42M | -$1.08B | -$219.17M |
| Basic EPS | -$0.26 | -$0.28 | -$0.24 | -$1.44 | -$0.29 |
| Diluted EPS | -$0.26 | -$0.28 | -$0.24 | -$1.44 | -$0.29 |
| Other Non-Operating Income (Expenses) | – | $500,000.00 | – | -$53,000.00 | $0.00 |
| Net Non-Operating Interest Income (Expense) | – | – | – | $0.00 | $0.00 |
| Non-Operating Interest Expense | – | – | – | $0.00 | $0.00 |
| Special Income (Charges) | – | – | – | $0.00 | $0.00 |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $692.85M | $752.19M | $647.86M | $751.18M | $751.18M |
| Total Current Assets | $660.73M | $720.58M | $616.60M | $720.30M | $720.30M |
| Cash and Cash Equivalents & Short-Term Investments | $629.79M | $690.68M | $598.73M | $713.45M | $713.45M |
| -Cash and Cash Equivalents | $150.81M | $419.37M | $106.52M | $225.27M | $225.27M |
| -Short Term Investments | $478.98M | $271.31M | $492.22M | $488.18M | $488.18M |
| Restricted Cash | $316,000.00 | $317,000.00 | $316,000.00 | $316,000.00 | $316,000.00 |
| Other Current Assets | $30.63M | $29.58M | $17.55M | $6.54M | $6.54M |
| Total Non-Current Assets | $32.12M | $31.61M | $31.26M | $30.88M | $30.88M |
| Net PPE | $21.19M | $21.19M | $21.06M | $21.68M | $21.68M |
| -Gross PPE | $21.19M | $21.19M | $21.06M | $21.68M | $21.68M |
| Goodwill and Other Intangible Assets | $1.98M | $1.97M | $1.97M | $2.00M | $2.00M |
| -Goodwill | $1.98M | $1.97M | $1.97M | $2.00M | $2.00M |
| Other Non-Current Assets | $8.96M | $8.45M | $8.23M | $7.21M | $7.21M |
| Total Liabilities | $128.17M | $122.20M | $101.92M | $92.32M | $92.32M |
| Total Current Liabilities | $110.23M | $103.57M | $83.27M | $72.99M | $72.99M |
| Payables | $32.72M | $22.90M | $27.55M | $20.29M | $20.29M |
| -Accounts Payable | $32.72M | $22.90M | $27.55M | $20.29M | $20.29M |
| Current Accrued Expenses | $55.93M | $65.06M | $44.32M | $32.10M | $32.10M |
| Short-Term Debt and Capital Lease Obligation | $3.85M | $3.55M | $3.18M | $3.39M | $3.39M |
| -Current Capital Lease Obligation | $3.85M | $3.55M | $3.18M | $3.39M | $3.39M |
| Other Current Liabilities | $1.83M | $2.62M | $1.15M | $2.28M | $2.28M |
| Total Non-Current Liabilities | $17.94M | $18.64M | $18.66M | $19.33M | $19.33M |
| Long Term Debt and Capital Lease Obligation | $16.13M | $16.83M | $16.86M | $17.50M | $17.50M |
| -Long Term Capital Lease Obligation | $16.13M | $16.83M | $16.86M | $17.50M | $17.50M |
| Other Non-Current Liabilities | $1.81M | $1.80M | $1.80M | $1.83M | $1.83M |
| Total Equity | $564.68M | $629.98M | $545.93M | $658.86M | $658.86M |
| Stockholders' Equity | $564.68M | $629.98M | $545.93M | $658.86M | $658.86M |
| Capital Stock | $8.00M | $7.93M | $7.76M | $7.75M | $7.75M |
| -Common Stock | $8.00M | $7.93M | $7.76M | $7.75M | $7.75M |
| -Preferred Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Additional Paid-In Capital | $3.47B | $3.32B | $3.02B | $2.95B | $2.95B |
| Retained Earnings | -$2.91B | -$2.70B | -$2.48B | -$2.29B | -$2.29B |
| Gains/Losses Not Affecting Retained Earnings | -$2.70M | -$2.67M | -$2.63M | -$2.54M | -$2.54M |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$159.81M | -$141.12M | -$122.29M | -$322.93M | -$101.94M |
| Net cash flow from continuing operations | -$159.81M | -$141.12M | -$122.29M | -$322.93M | -$101.94M |
| Net Income from Continuing Operations | -$208.39M | -$215.70M | -$189.42M | -$1.08B | -$219.17M |
| Gain/Loss from Continuing Operations | $10,000.00 | $30,000.00 | $190,000.00 | -$320,000.00 | $94,000.00 |
| Depreciation & Depletion & Amortization | $85,000.00 | $46,000.00 | $44,000.00 | $146,000.00 | $42,000.00 |
| Change in Working Capital | $4.73M | $8.76M | -$1.68M | $31.42M | $8.34M |
| -Change in Prepaid Assets | -$1.04M | -$12.03M | -$11.01M | $4.87M | $1.21M |
| -Change in Payables and Accrued Expense | $6.72M | $19.20M | $11.17M | $31.14M | $7.34M |
| -Change in Other Current Assets | -$510,000.00 | -$217,000.00 | -$1.03M | -$4.88M | -$347,000.00 |
| -Change in Other Current Liabilities | -$788,000.00 | $1.48M | -$1.17M | $80,000.00 | -$136,000.00 |
| -Change In Other Working Capital | $350,000.00 | $335,000.00 | $365,000.00 | $203,000.00 | $267,000.00 |
| Net cash flow from investing | -$204.16M | $222.90M | -$238,000.00 | -$174.31M | -$485.16M |
| Net Cash Flow from Continuing Investing Activities | -$204.16M | $222.90M | -$238,000.00 | -$174.31M | -$485.16M |
| Net PPE Purchase and Sale | -$396,000.00 | -$909,000.00 | -$245,000.00 | -$657,000.00 | -$164,000.00 |
| Net Investment Purchase and Sale | -$203.77M | $223.81M | $7,000.00 | -$173.65M | -$484.99M |
| Financing Cash Flow | $95.43M | $231.08M | $3.80M | $617.53M | $573.82M |
| Net Cash Flow from Continuing Financing Activities | $95.43M | $231.08M | $3.80M | $617.53M | $573.82M |
| Net Common Stock Issuance | $92.83M | – | – | $604.57M | $572.80M |
| Proceeds from Stock Option Exercised | $2.60M | $3.67M | $3.80M | $12.97M | $1.02M |
| Ending Cash Balance | $151.13M | $419.68M | $106.83M | $225.58M | $225.58M |
| Net Change in Cash | -$268.55M | $312.85M | -$118.73M | $120.29M | -$13.27M |
| Beginning Cash Balance | $419.68M | $106.83M | $225.58M | $105.19M | $238.88M |
| Effect of Exchange Rate Changes | -$9,000.00 | $1,000.00 | -$19,000.00 | $102,000.00 | -$19,000.00 |
| Free Cash Flow | -$160.21M | -$142.03M | -$122.54M | -$323.59M | -$102.10M |
| Net Issuance Payments Of Debt | – | – | – | $0.00 | $0.00 |
No comments yet — be the first to weigh in on SMMT.
Sign in to join the discussion.